Centanafadine's ADHD approval, the MDMA NDA resubmission, DT120 phase 3 wins, and the FDA psychedelic hearing headline Q3 2026 psychiatry news.
News|Articles|October 2, 2026
5 Psychiatry Headlines You Missed in September 2026
Author(s)Chelsie Derman
Fact checked by: Tim Smith
Here, we review the top psychiatry news in September 2026, from DT120's second Breakthrough Therapy designation to the FDA psychedelic hearing.
Advertisement
Advertisement
September brought regulatory and research momentum for psychedelic therapies in psychiatry. The US Food & Drug Administration (FDA) granted DT120 (lysergide) orally disintegrating tablet (ODT) a second Breakthrough Therapy designation, this time in
Related to this article
Weltruza requires no loading doses, oral supplementation, or post-injection monitoring, with approval based on the phase 3 SOLARIS trial.
Two-year ICONIC-LEAD data show oral icotrokinra sustained PASI 90 and IGA 0/1 responses in more than 70% of adults and adolescents with plaque psoriasis.
New TOGETHER-PsO data show ixekizumab plus tirzepatide drove broader immune and metabolic biomarker changes than ixekizumab alone in psoriasis and obesity.
Jasmohan Bajaj, MD, joins Nancy Reau, MD, and Kim Brown, MD, to review what is new in the ACG hepatic encephalopathy guideline.
Lasker Award winners Takehisa Kitazawa and Tomoyuki Igawa discuss prophylaxis gains, remaining unmet needs, and lessons for drug discovery.
In the phase 3 RAPIDe-3 trial published in The Lancet, median time to symptom relief was 1.28 hours with deucrictibant vs more than 12 hours with placebo.
Lasker Award winners Kunihiro Hattori, Takehisa Kitazawa, and Tomoyuki Igawa recount the 2400 variants behind the drug.
Advertisement
Advertisement